relacatib
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00411190)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cathepsin KINHIBITOR
CTSK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1CC[C@@H](C)N(S(=O)(=O)c2ccccn2)CC1=O- Mol. weight
- 540.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL203665 ↗
Also known as
- n-((1s)-3-methyl-1-((((4s,7r)-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)hexahydro-1h-azepin-4-yl)amino)carbonyl)-butyl)-1-benzofuran-2-carboxamide
- relacatib
- relacatib
- relacatib
- relacatib
- sb462795
- sb 462795
- sb-462795
- sb-462795
- sb-462795
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00411190 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1